165 related articles for article (PubMed ID: 32108693)
1. Intense 68Ga-Pentixafor Activity in Aldosterone-Producing Adrenal Adenomas.
Ding J; Tong A; Zhang Y; Wen J; Huo L
Clin Nucl Med; 2020 Apr; 45(4):336-339. PubMed ID: 32108693
[TBL] [Abstract][Full Text] [Related]
2. Cortisol-Producing Adrenal Adenomas With Intense Activity on 68Ga-Pentixafor PET/CT.
Ding J; Tong A; Zhang Y; Zhang H; Huo L
Clin Nucl Med; 2021 Apr; 46(4):350-352. PubMed ID: 33492858
[TBL] [Abstract][Full Text] [Related]
3. Imaging Aldosterone-Producing Adrenocortical Carcinoma With 68 Ga-Pentixafor PET/CT.
Shu Q; Deng M; Chen Y; Liu N; Cai L
Clin Nucl Med; 2022 Aug; 47(8):e572-e573. PubMed ID: 35426842
[TBL] [Abstract][Full Text] [Related]
4. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma.
Heinze B; Fuss CT; Mulatero P; Beuschlein F; Reincke M; Mustafa M; Schirbel A; Deutschbein T; Williams TA; Rhayem Y; Quinkler M; Rayes N; Monticone S; Wild V; Gomez-Sanchez CE; Reis AC; Petersenn S; Wester HJ; Kropf S; Fassnacht M; Lang K; Herrmann K; Buck AK; Bluemel C; Hahner S
Hypertension; 2018 Feb; 71(2):317-325. PubMed ID: 29279316
[TBL] [Abstract][Full Text] [Related]
5. Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using
Ding J; Tong A; Zhang Y; Wen J; Zhang H; Hacker M; Huo L; Li X
J Nucl Med; 2022 Mar; 63(3):368-375. PubMed ID: 34301781
[TBL] [Abstract][Full Text] [Related]
6. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
[TBL] [Abstract][Full Text] [Related]
7. Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With Waldenström Macroglobulinemia.
Luo Y; Pan Q; Feng J; Cao X; Li F
Clin Nucl Med; 2018 Jul; 43(7):548-550. PubMed ID: 29742593
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of 68 Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome.
Ding J; Tong A; Hacker M; Feng M; Huo L; Li X
Clin Nucl Med; 2022 Aug; 47(8):669-676. PubMed ID: 35452014
[TBL] [Abstract][Full Text] [Related]
9. The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism.
Zheng Y; Long T; Peng N; Zhen M; Ye Q; Zhang Z; He Y; Chen Z; Gan Y; Luo M; Li C; Liu Z; Guo M; Wang M; Luo X; Hu S; Liu L; Jiang T
J Clin Endocrinol Metab; 2023 Dec; 109(1):171-182. PubMed ID: 37477496
[TBL] [Abstract][Full Text] [Related]
10. CXCR4-directed [
Chaman Baz AH; van de Wiel E; Groenewoud H; Arntz M; Gotthardt M; Deinum J; Langenhuijsen J
BMJ Open; 2022 Aug; 12(8):e060779. PubMed ID: 35998969
[TBL] [Abstract][Full Text] [Related]
11. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.
Lapa C; Lückerath K; Rudelius M; Schmid JS; Schoene A; Schirbel A; Samnick S; Pelzer T; Buck AK; Kropf S; Wester HJ; Herrmann K
Oncotarget; 2016 Feb; 7(8):9288-95. PubMed ID: 26843617
[TBL] [Abstract][Full Text] [Related]
12. Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach.
Linde P; Baues C; Wegen S; Trommer M; Quaas A; Rosenbrock J; Celik E; Marnitz S; Bruns CJ; Fischer T; Schomaecker K; Wester HJ; Drzezga A; van Heek L; Kobe C
Cancer Imaging; 2021 Feb; 21(1):22. PubMed ID: 33579381
[TBL] [Abstract][Full Text] [Related]
13. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.
Lapa C; Lückerath K; Kleinlein I; Monoranu CM; Linsenmann T; Kessler AF; Rudelius M; Kropf S; Buck AK; Ernestus RI; Wester HJ; Löhr M; Herrmann K
Theranostics; 2016; 6(3):428-34. PubMed ID: 26909116
[TBL] [Abstract][Full Text] [Related]
14. Imaging Inflammation in Atherosclerosis with CXCR4-Directed
Kircher M; Tran-Gia J; Kemmer L; Zhang X; Schirbel A; Werner RA; Buck AK; Wester HJ; Hacker M; Lapa C; Li X
J Nucl Med; 2020 May; 61(5):751-756. PubMed ID: 31653710
[TBL] [Abstract][Full Text] [Related]
15. [
Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
[TBL] [Abstract][Full Text] [Related]
16.
Luo Y; Cao X; Pan Q; Li J; Feng J; Li F
J Nucl Med; 2019 Dec; 60(12):1724-1729. PubMed ID: 31101745
[No Abstract] [Full Text] [Related]
17. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [
Haug AR; Leisser A; Wadsak W; Mitterhauser M; Pfaff S; Kropf S; Wester HJ; Hacker M; Hartenbach M; Kiesewetter-Wiederkehr B; Raderer M; Mayerhoefer ME
Theranostics; 2019; 9(12):3653-3658. PubMed ID: 31281504
[TBL] [Abstract][Full Text] [Related]
18.
Bouter C; Meller B; Sahlmann CO; Staab W; Wester HJ; Kropf S; Meller J
J Nucl Med; 2018 Feb; 59(2):320-326. PubMed ID: 28729430
[TBL] [Abstract][Full Text] [Related]
19. Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT.
Pan Q; Luo Y; Cao X; Ma Y; Li F
Clin Nucl Med; 2018 Jun; 43(6):462-463. PubMed ID: 29538035
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas.
Burton TJ; Mackenzie IS; Balan K; Koo B; Bird N; Soloviev DV; Azizan EA; Aigbirhio F; Gurnell M; Brown MJ
J Clin Endocrinol Metab; 2012 Jan; 97(1):100-9. PubMed ID: 22112805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
